Pharmacotherapeutics for Advanced Practice Nurse Prescribers, 5th edition Woo Robinson Test
n n n n n n n n n nn
Bank
n
Chapter 1. The Role of the Nurse Practitioner as Pre
n n n n n n n n nn
scriberMultiple Choice n
Identifynthen choicen thatn bestn completesn then statementn orn answersn then question.
n 1.n Nursen practitionern prescriptiven authorityn isn regulated n by:
1. Then Nationaln Counciln of n Staten Boardsn of n Nursing
2. Then U.S.n Drugn Enforcement n Administration
3. Then Staten Board n of n Nursingn forn eachn state
4. Then Staten Board n of n Pharmacy
n 2.n Then benefitsn tonthenpatient nofnhavingnann Advanced nPracticen Registered n Nursen (APRN)nprescribern i
nclude:
1. Nursesn known moren about n Pharmacologynthann othern prescribersn becausen theyntakenit n
bothn inn theirn basicn nursingn programn and n inn theirn APRN n program.
2. Nursesn caren forn thenpatient nfromn anholisticn approachn andnincludenthenpatient ninnd
ecisionn makingn regardingn theirn care.
3. APRNsn aren lessn likelynton prescriben narcoticsn and n othern controlled n substances.
4. APRNsn arenablenton prescriben independentlyn inn alln states,n whereasn an physician’sn
assistant n needsn ton haven an physiciann supervisingn theirn practice.
n 3.n Clinicaln judgment n inn prescribingn includes:
1. Factoringninn then cost n ton then patient n of n then medicationn prescribed
2. Alwaysn prescribingn then newest n medicationn availablen forn then diseasen process
3. Handingn out n drugn samplesn ton poorn patients
4. Prescribingn alln genericn medicationsn ton cut n costs
n 4.n Criterian forn choosingn ann effectiven drugn forn an disordern include:
1. Askingn then patient n what n drugn theyn thinkn would n workn best n forn them
2. Consultingn nationallyn recognized n guidelinesn forn diseasen management
3. Prescribingnmedicationsn that n aren availablen asn samplesn beforen writingn an prescription
4. FollowingnU.S.n Drugn Enforcement n Administrationn guidelinesn forn prescribing
n 5.n Nursen practitionern practicen mayn thriven undern health-caren reformn becausen of:
1. Thendemonstrated n abilitynof n nursenpractitionersn ton controlncostsn and n improvenpatient n
outcomes
2. Thenfact n that n nursen practitionersn willn ben ablen ton practicen independently
3. Thenfact n that n nursen practitionersn willn havenfulln reimbursement n undern health-
n caren reform
4. Thenabilityn ton shift n accountabilityn forn Medicaid n ton then staten level
,Chaptern1.nThenRolenof nthenNursenPractitionernasnPrescribern
AnswernSection
MULTIPLEnCHOICE
1.n ANS: 3 PTS: 1
2.n ANS: 2 PTS: 1
3.n ANS: 1 PTS: 1
4.n ANS: 2 PTS: 1
5.n ANS: 1 PTS: 1
,Chaptern2.nReview nof nthenBasicnPrinciplesnof nPharmacology
MultiplenChoice
Identifynthen choicen thatn bestn completesn then statementn orn answersn then question.
n 1.n A n patient’sn nutritionaln intakenandnlaboratorynresultsn reflect n hypoalbuminemia.n Thisn isn criticaln ton p
rescribingn because:
1. Distributionn of n drugsn ton target n tissuen mayn ben affected.
2. Then solubilityn of n then drugn willn not n matchn then siten of n absorption.
3. Theren willn ben lessn freen drugn availablen ton generaten ann effect.
4. Drugsn bound n ton albuminn aren readilyn excreted n byn then kidneys.
n 2.n Drugsn that n haven an significant n first-passn effect:
1. Must n ben givenn byn then enteraln (oral)n routen only
2. Bypassn then hepaticn circulation
3. Arenrapidlyn metabolized n byn then livern and n mayn haven littlen if n anyn desired n action
4. Aren converted n byn then livern ton moren activen and n fat-solublen forms
n 3.n Then routen of n excretionn of n an volatilen drugn willn likelyn ben the:
1. Kidneys
2. Lungs
3. Bilenand n feces
4. Skin
n 4.n Medroxyprogesteronen (DeponProvera)n isn prescribed n intramuscularlyn(IM)n ton createnanstoragen r
eservoirn of n then drug.n Storagen reservoirs:
1. Assurenthat n then drugn willn reachn itsn intended n target n tissue
2. Arenthen reasonn forn givingn loadingn doses
3. Increasen then lengthn of n timen an drugn isn availablen and n active
4. Arenmost n commonn inn collagenn tissues
n 5.n Then NPn choosesn ton given cephalexinn everyn 8n hoursn based n onn knowledgen of n then drug’s:
1. Propensitynton gon ton then target n receptor
2. Biologicalnhalf-life
3. Pharmacodynamics
4. Safetyn and n siden effects
n 6.n Azithromycinn dosingn requiresn that nthen first nday’sn dosagen bentwicenthosenofnthenothern 4ndaysnof nthenpr
escription.n Thisn isn considered n an loadingn dose.n An loadingn dose:
1. Rapidlynachievesn drugn levelsn inn then therapeuticn range
2. Requiresn four-n ton five-half-livesn ton attain
3. Isn influenced n bynrenaln function
4. Isn directlyn related n ton then drugn circulatingn ton then target n tissues
n 7.n Then point n inn timen onnthendrugn concentrationn curven that nindicatesn then first nsignn of nantherapeuticn effect nisn
the:
1. Minimumn adversen effect n level
2. Peakn of n action
, 3. Onset n of n action
4. Therapeuticnrange
n 8.n Phenytoinn requiresn that n an troughn leveln ben drawn.n Peakn and n troughn levelsn aren done:
1. Whenn then drugn hasn an widen therapeuticn range
2. Whenn then drugn willn ben administered n forn an short n timen only
3. Whenn theren isn an highn correlationn betweenn then dosen and n saturationn of n receptorn sites
4. Ton determinen if n an drugn isn inn then therapeuticn range
n 9.n A n laboratoryn result n indicatesn that n then peakn leveln forn an drugn isn aboven then minimumn toxicnconcentration.
Thisn meansn that n the:
1. Concentrationnwilln producen therapeuticn effects
2. Concentrationn willn producen ann adversen response
3. Timen betweenn dosesn must n ben shortened
4. Durationn of n actionn of n then drugn isn toon long
10.n Drugsn that n aren receptorn agonistsn mayn demonstraten what n property?
n
1. Irreversiblen bindingn ton then drugn receptorn site
2. Upregulationn withn chronicn use
3. Desensitizationn orn downregulationn withn continuousn use
4. Inversen relationshipn betweenn drugn concentrationn and n drugn action
11.n Drugsn that n aren receptorn antagonists,n suchn asn betan blockers,n mayn cause:
n
1. Downregulationn of n then drugn receptor
2. Ann exaggerated n responsen if n abruptlyn discontinued
3. Partialn blockaden of n then effectsn of n agonist n drugs
4. Ann exaggerated n responsen ton competitiven drugn agonists
12.n Factorsn that n affect n gastricn drugn absorptionn include:
n
1. Livernenzymen activity
2. Protein-bindingn propertiesn of n then drugn molecule
3. Lipid n solubilitynof n then drug
4. Abilitynton chew n and n swallow
13.n Drugsn administered n vian IV:
n
1. Need n ton ben lipid n solublen inn ordern ton ben easilyn absorbed
2. Beginn distributionn inton then bodyn immediately
3. Aren easilyn absorbed n if n theyn aren nonionized
4. Mayn usen pinocytosisn ton ben absorbed
14.n Whenn an medicationn isn added n ton an regimenn forn an synergisticn effect,n then combined n effect n of n then drugsnis:
n
1. Then sumn of n then effectsn of n eachn drugn individually
2. Greatern thann then sumn of n then effectsn of n eachn drugn individually
3. Lessn thann then effect n of n eachn drugn individually
4. Not npredictable,n asn it n variesn withn eachn individual
15.n Whichn of n then followingn statementsn about n bioavailabilityn isn true?
n
1. Bioavailabilitynissuesn arenespeciallynimportant nforndrugsn withn narrow ntherapeuticn r
angesn orn sustained-releasen mechanisms.
2. Allnbrandsn of n an drugn haven then samen bioavailability.
3. Drugsn that n aren administered n moren thann oncen an dayn haven greatern bioavailabilitynthan
n n n n n n n n n nn
Bank
n
Chapter 1. The Role of the Nurse Practitioner as Pre
n n n n n n n n nn
scriberMultiple Choice n
Identifynthen choicen thatn bestn completesn then statementn orn answersn then question.
n 1.n Nursen practitionern prescriptiven authorityn isn regulated n by:
1. Then Nationaln Counciln of n Staten Boardsn of n Nursing
2. Then U.S.n Drugn Enforcement n Administration
3. Then Staten Board n of n Nursingn forn eachn state
4. Then Staten Board n of n Pharmacy
n 2.n Then benefitsn tonthenpatient nofnhavingnann Advanced nPracticen Registered n Nursen (APRN)nprescribern i
nclude:
1. Nursesn known moren about n Pharmacologynthann othern prescribersn becausen theyntakenit n
bothn inn theirn basicn nursingn programn and n inn theirn APRN n program.
2. Nursesn caren forn thenpatient nfromn anholisticn approachn andnincludenthenpatient ninnd
ecisionn makingn regardingn theirn care.
3. APRNsn aren lessn likelynton prescriben narcoticsn and n othern controlled n substances.
4. APRNsn arenablenton prescriben independentlyn inn alln states,n whereasn an physician’sn
assistant n needsn ton haven an physiciann supervisingn theirn practice.
n 3.n Clinicaln judgment n inn prescribingn includes:
1. Factoringninn then cost n ton then patient n of n then medicationn prescribed
2. Alwaysn prescribingn then newest n medicationn availablen forn then diseasen process
3. Handingn out n drugn samplesn ton poorn patients
4. Prescribingn alln genericn medicationsn ton cut n costs
n 4.n Criterian forn choosingn ann effectiven drugn forn an disordern include:
1. Askingn then patient n what n drugn theyn thinkn would n workn best n forn them
2. Consultingn nationallyn recognized n guidelinesn forn diseasen management
3. Prescribingnmedicationsn that n aren availablen asn samplesn beforen writingn an prescription
4. FollowingnU.S.n Drugn Enforcement n Administrationn guidelinesn forn prescribing
n 5.n Nursen practitionern practicen mayn thriven undern health-caren reformn becausen of:
1. Thendemonstrated n abilitynof n nursenpractitionersn ton controlncostsn and n improvenpatient n
outcomes
2. Thenfact n that n nursen practitionersn willn ben ablen ton practicen independently
3. Thenfact n that n nursen practitionersn willn havenfulln reimbursement n undern health-
n caren reform
4. Thenabilityn ton shift n accountabilityn forn Medicaid n ton then staten level
,Chaptern1.nThenRolenof nthenNursenPractitionernasnPrescribern
AnswernSection
MULTIPLEnCHOICE
1.n ANS: 3 PTS: 1
2.n ANS: 2 PTS: 1
3.n ANS: 1 PTS: 1
4.n ANS: 2 PTS: 1
5.n ANS: 1 PTS: 1
,Chaptern2.nReview nof nthenBasicnPrinciplesnof nPharmacology
MultiplenChoice
Identifynthen choicen thatn bestn completesn then statementn orn answersn then question.
n 1.n A n patient’sn nutritionaln intakenandnlaboratorynresultsn reflect n hypoalbuminemia.n Thisn isn criticaln ton p
rescribingn because:
1. Distributionn of n drugsn ton target n tissuen mayn ben affected.
2. Then solubilityn of n then drugn willn not n matchn then siten of n absorption.
3. Theren willn ben lessn freen drugn availablen ton generaten ann effect.
4. Drugsn bound n ton albuminn aren readilyn excreted n byn then kidneys.
n 2.n Drugsn that n haven an significant n first-passn effect:
1. Must n ben givenn byn then enteraln (oral)n routen only
2. Bypassn then hepaticn circulation
3. Arenrapidlyn metabolized n byn then livern and n mayn haven littlen if n anyn desired n action
4. Aren converted n byn then livern ton moren activen and n fat-solublen forms
n 3.n Then routen of n excretionn of n an volatilen drugn willn likelyn ben the:
1. Kidneys
2. Lungs
3. Bilenand n feces
4. Skin
n 4.n Medroxyprogesteronen (DeponProvera)n isn prescribed n intramuscularlyn(IM)n ton createnanstoragen r
eservoirn of n then drug.n Storagen reservoirs:
1. Assurenthat n then drugn willn reachn itsn intended n target n tissue
2. Arenthen reasonn forn givingn loadingn doses
3. Increasen then lengthn of n timen an drugn isn availablen and n active
4. Arenmost n commonn inn collagenn tissues
n 5.n Then NPn choosesn ton given cephalexinn everyn 8n hoursn based n onn knowledgen of n then drug’s:
1. Propensitynton gon ton then target n receptor
2. Biologicalnhalf-life
3. Pharmacodynamics
4. Safetyn and n siden effects
n 6.n Azithromycinn dosingn requiresn that nthen first nday’sn dosagen bentwicenthosenofnthenothern 4ndaysnof nthenpr
escription.n Thisn isn considered n an loadingn dose.n An loadingn dose:
1. Rapidlynachievesn drugn levelsn inn then therapeuticn range
2. Requiresn four-n ton five-half-livesn ton attain
3. Isn influenced n bynrenaln function
4. Isn directlyn related n ton then drugn circulatingn ton then target n tissues
n 7.n Then point n inn timen onnthendrugn concentrationn curven that nindicatesn then first nsignn of nantherapeuticn effect nisn
the:
1. Minimumn adversen effect n level
2. Peakn of n action
, 3. Onset n of n action
4. Therapeuticnrange
n 8.n Phenytoinn requiresn that n an troughn leveln ben drawn.n Peakn and n troughn levelsn aren done:
1. Whenn then drugn hasn an widen therapeuticn range
2. Whenn then drugn willn ben administered n forn an short n timen only
3. Whenn theren isn an highn correlationn betweenn then dosen and n saturationn of n receptorn sites
4. Ton determinen if n an drugn isn inn then therapeuticn range
n 9.n A n laboratoryn result n indicatesn that n then peakn leveln forn an drugn isn aboven then minimumn toxicnconcentration.
Thisn meansn that n the:
1. Concentrationnwilln producen therapeuticn effects
2. Concentrationn willn producen ann adversen response
3. Timen betweenn dosesn must n ben shortened
4. Durationn of n actionn of n then drugn isn toon long
10.n Drugsn that n aren receptorn agonistsn mayn demonstraten what n property?
n
1. Irreversiblen bindingn ton then drugn receptorn site
2. Upregulationn withn chronicn use
3. Desensitizationn orn downregulationn withn continuousn use
4. Inversen relationshipn betweenn drugn concentrationn and n drugn action
11.n Drugsn that n aren receptorn antagonists,n suchn asn betan blockers,n mayn cause:
n
1. Downregulationn of n then drugn receptor
2. Ann exaggerated n responsen if n abruptlyn discontinued
3. Partialn blockaden of n then effectsn of n agonist n drugs
4. Ann exaggerated n responsen ton competitiven drugn agonists
12.n Factorsn that n affect n gastricn drugn absorptionn include:
n
1. Livernenzymen activity
2. Protein-bindingn propertiesn of n then drugn molecule
3. Lipid n solubilitynof n then drug
4. Abilitynton chew n and n swallow
13.n Drugsn administered n vian IV:
n
1. Need n ton ben lipid n solublen inn ordern ton ben easilyn absorbed
2. Beginn distributionn inton then bodyn immediately
3. Aren easilyn absorbed n if n theyn aren nonionized
4. Mayn usen pinocytosisn ton ben absorbed
14.n Whenn an medicationn isn added n ton an regimenn forn an synergisticn effect,n then combined n effect n of n then drugsnis:
n
1. Then sumn of n then effectsn of n eachn drugn individually
2. Greatern thann then sumn of n then effectsn of n eachn drugn individually
3. Lessn thann then effect n of n eachn drugn individually
4. Not npredictable,n asn it n variesn withn eachn individual
15.n Whichn of n then followingn statementsn about n bioavailabilityn isn true?
n
1. Bioavailabilitynissuesn arenespeciallynimportant nforndrugsn withn narrow ntherapeuticn r
angesn orn sustained-releasen mechanisms.
2. Allnbrandsn of n an drugn haven then samen bioavailability.
3. Drugsn that n aren administered n moren thann oncen an dayn haven greatern bioavailabilitynthan
